Adjuvant Nivolumab in Esophageal Cancer — A New Standard of Care
Mené sur 532 patients atteints d'un cancer de l'oesophage ou d'un cancer de la jonction oesogastrique ayant été réséqué, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans maladie, et la toxicité du nivolumab en traitement adjuvant
Esophageal cancer is a leading cause of cancer-related illness and death throughout the world. Because there is no effective screening or early detection, most patients present with locally advanced or overt metastatic disease. Esophageal squamous-cell carcinoma is the most common histologic type worldwide in high-incidence areas such as East Asia, and adenocarcinoma is the dominant histologic type in the West. A review of surgical outcomes in nearly 84,000 patients with esophageal squamous-cell cancer in 1980 indicated the daunting challenge of treating esophageal cancer (....)
New England Journal of Medicine , éditorial, 2020